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SUMMARY
In this study we aimed to compare patient and graft survival of kidney trans-
plant recipients who received a kidney from a living-related donor (LRD) or
living-unrelated donor (LUD). Adult patients in the ERA-EDTA Registry
who received their first kidney transplant in 1998–2017 were included. Ten-
year patient and graft survival were compared between LRD and LUD
transplants using Cox regression analysis. In total, 14 370 patients received a
kidney from a living donor. Of those, 9212 (64.1%) grafts were from a LRD,
5063 (35.2%) from a LUD and for 95 (0.7%), the donor type was unknown.
Unadjusted five-year risks of death and graft failure (including death as
event) were lower for LRD transplants than for LUD grafts: 4.2% (95% confi-
dence interval [CI]: 3.7–4.6) and 10.8% (95% CI: 10.1–11.5) versus 6.5%
(95% CI: 5.7–7.4) and 12.2% (95% CI: 11.2–13.3), respectively. However,
after adjusting for potential confounders, associations disappeared with haz-
ard ratios of 0.99 (95% CI: 0.87–1.13) for patient survival and 1.03 (95% CI:
0.94–1.14) for graft survival. Unadjusted risk of death-censored graft failure
was similar, but after adjustment, it was higher for LUD transplants (1.19;
95% CI: 1.04–1.35). In conclusion, patient and graft survival of LRD and
LUD kidney transplant recipients was similar, whereas death-censored graft
failure was higher in LUD. These findings confirm the importance of both
living kidney donor types.
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Introduction
The increasing incidence of end-stage kidney disease
(ESKD) combined with the inadequate supply of
deceased donor kidneys has led to a call for an expan-
sion of the donor pool [1]. Living kidney donation has
the potential to increase the donor pool, thereby reduc-
ing the waiting time for a kidney transplant [2]. Kid-
neys from living donors most commonly originate from
genetically related individuals (living-related donors,
LRD), such as parents, children or siblings. Living
donation can also come from a living-unrelated donor
(LUD). This may be someone who is emotionally
related to the recipient, for example a spouse or a
friend, but can also be an unrelated and even unac-
quainted person, such as a donor via a paired or pooled
donation programme or an altruistic donor. Previous
studies investigated the effect of the living donor source
on patient and graft survival, the majority of which
have shown similar patient and graft survival for recipi-
ents of kidneys from LUD when compared to LRD [3–
9]. By contrast, one study demonstrated better patient
survival among recipients of kidneys from LRD com-
pared to those from LUD [10]. However, most previous
studies were performed in relatively small patient sam-
ples, often from a single centre, and therefore may have
lacked the statistical power required to detect relevant
differences, or may have represented a selected popula-
tion.
To the best of our knowledge, there are no large
multinational studies available that have investigated the
effect of living donor source on the survival of kidney
transplant recipients. In this study, we used data from
the European Renal Association-European Dialysis and
Transplant Association (ERA-EDTA) Registry to com-
pare patient and graft survival of kidney transplant
recipients who received a kidney from a LRD with those
transplanted with a graft from a LUD. In addition, we
aimed to examine trends over time and to identify dif-
ferences in causes of death between these two groups.
Patients and methods
Study population
For this study, we used data from the ERA-EDTA Reg-
istry. It includes data from the 21 national and regional
renal registries with complete information on living
donor source available: Austria, Dutch and French-
speaking Belgium, Bosnia and Herzegovina, Denmark,
Finland, France (only if the concerning region was par-
ticipating in the French REIN registry in the year of the
transplantation), Greece, Iceland, Norway, Sweden,
Scotland (UK) and the Spanish regions of Andalusia,
Aragon, Asturias, Catalonia, Cantabria, Extremadura,
Galicia, Madrid and Murcia. These registries provide
data on patients receiving kidney replacement therapy
(KRT) for ESKD to the ERA-EDTA Registry on an
annual basis [11].
We included all adult patients (aged 20 years or
older) who received their first kidney transplant from a
living donor between 1 January 1998 and 31 December
2017. The transplant recipients were classified into two
groups according to donor source: LRD and LUD.
Data collection and definitions
The core data set of the ERA-EDTA Registry includes
the month and year of birth, sex, primary renal disease
(PRD), treatment modality at the start of KRT, changes
in KRT modality and date and cause of death. There
were no missing values for month/year of birth, sex,
PRD and treatment modality. Age at kidney transplan-
tation was categorized into four groups: 20–44, 45–64,
65–74 and ≥ 75 years. The PRD was classified according
to the coding system of the ERA-EDTA and was
2 Transplant International 2020;
ª 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT
Abd ElHafeez et al.
categorized into ten groups: glomerulonephritis/sclero-
sis, pyelonephritis, polycystic kidneys, adult type, dia-
betes mellitus type I, diabetes mellitus type II,
hypertension, renal vascular disease, miscellaneous and
unknown/missing. For survival analysis, the PRD was
categorized into four groups: glomerulonephritis, dia-
betes mellitus, hypertension/ renal vascular disease and
other causes. To study the influence of calendar time,
the year of kidney transplantation was divided into two
time periods, 1998–2007 and 2008–2017. The causes of
death were classified using the coding system of the
ERA-EDTA and grouped into the following categories:
cardiovascular disease (including myocardial ischaemia
and infarction, heart failure and cardiac arrest), cere-
brovascular accident, infection, cachexia, malignancies,
miscellaneous (including suicide) and unknown/unavail-
able. The ERA-EDTA Registry data set does not include
information on donors (e.g. age, comorbidity) or details
on transplantations (e.g. human leucocyte antigen
(HLA) matching, cold ischaemia time).
Statistical analysis
The results are expressed as mean and standard devia-
tion (SD) in case of normally distributed data, median
and interquartile range (IQR) for non-normally dis-
tributed data, or as percentage for categorical data.
Comparisons between groups were made using indepen-
dent t-tests (normally distributed data), Mann–Whitney
tests (non-normally distributed data) or chi-squared
tests (categorical data).
The distribution of causes of death was analysed for
those registries with less than 25% missing or unknown
causes of death and the analysis of the causes of death
included all countries and regions except France.
LRD and LUD kidney transplantation rates were cal-
culated as the number of transplants performed divided
by the general population in millions. Time trends of
the transplantation rates were analysed using the Join-
point regression program [12]. Joinpoint regression is
based on Poisson distribution and identifies where a
change, a so-called ‘joinpoint’, in the trend occurs.
Changes in the slopes of these trends were calculated as
annual percentage change (APC) with a 95% confidence
interval (CI) for each segment [13]. For these analyses,
only those 14 national and regional registries that had
data on donor type available over the entire study per-
iod were included: Austria, Dutch- and French-speaking
Belgium, Denmark, Finland, Greece, Iceland, Norway,
Sweden, Scotland (UK) and the Spanish regions of
Andalusia, Asturias, Catalonia and Cantabria.
For all survival analyses, the date of the first kidney
transplantation was taken as the starting point, and
patients were followed until the event of interest, and
censored for loss to follow-up and the end of the study
period (31st December 2017) or follow-up period (five
or ten years). For patient survival, the event of interest
was all-cause death or death due to a specific cause. For
graft survival, the event of interest was graft loss (in-
cluding death with a functioning graft), while for death-
censored graft survival the event of interest was graft
loss and in this case death was considered a censored
observation. Retransplantation after failure of the first
graft was not taken into account. We performed
Kaplan–Meier and unadjusted and adjusted Cox pro-
portional-hazards analyses. For the latter, the propor-
tional-hazards assumptions were checked using
Shoenfeld residuals. Models were adjusted for recipient
age at kidney transplantation, sex, PRD, duration of
dialysis pre-transplant, country and era of first kidney
transplant (all as fixed effects). As a sensitivity analysis,
we repeated the aforementioned analyses using a 1:1
matching strategy in which patients were matched based
on age and year of transplantation (by 5-year periods).
Because the interaction between living donor type
and transplant era was statistically significant for patient
survival (P = 0.04), the 5-year patient and graft survival
was also analysed stratified by the time period of trans-
plantation (1998–2007 versus 2008–2017). In these anal-
yses, only those 14 national and regional registries that
had complete data available over the total study period
were included.
Finally, because a period on dialysis before kidney
transplantation may have influenced the outcomes stud-
ied, we repeated all analyses including only those
patients who received a pre-emptive transplant (i.e. kid-
ney transplantation before the start of any type of dialy-
sis treatment).
A two-tailed P-value < 0.05 was considered statisti-
cally significant. Analyses were performed using SAS
software version 9.4 (SAS Institute, Cary, NC, USA).
Results
Baseline characteristics
In total, there were 14 370 patients older than 20 years
who received a kidney transplant from a living donor
between 1998 and 2017. Of the living donor transplants,
9212 (64.5%) were from a LRD and 5063 (35.5%) from
a LUD. The remaining 95 patients (0.7%) received a
transplant from an unknown living donor source; the
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majority was from Catalonia (Spain, N = 36, 37.9%)
and Aragon (Spain, N = 28, 29.5%). These 95 patients
were excluded from further analyses.
The characteristics of the kidney transplant recipients
are presented in Table 1. At the start of KRT, LRD
transplant recipients were younger than LUD transplant






N, % 14 275 (100) 9212 (64.5) 5063 (35.5)
Sex, % male 9355 (65.5) 5877 (63.8) 3478 (68.7) <0.001
Age at onset of KRT in
years, median (IQR)
44.4 (32.9–55.1) 38.6 (29.2–49.8) 52.4 (44.5–60.0) <0.001
Age at onset of KRT, N (%) <0.001
0–20 years 159 (1.1) 151 (1.6) 8 (0.2)
20–44 years 7192 (50.4) 5866 (63.7) 1326 (26.2)
45–64 years 5947 (41.7) 2816 (30.6) 3131 (61.9)
65–74 years 924 (6.5) 360 (3.9) 564 (11.1)
≥75 years 46 (0.3) 13 (0.1) 33 (0.7)
Age at first KTx in years, median (IQR) 45.5 (34.1–56.2) 39.7 (30.4–51.0) 53.5 (45.7–61.0) <0.001
Pre-emptive KTx, N (%) 4602 (32.2) 2706 (29.4) 1896 (37.5) <0.001
Time on dialysis before first KTx
(months), median (IQR)
6.9 (0–17.7) 7.4 (0–17.8) 5.7 (0–17.5) <0.001
PRD (N, %) <0.001
Glomerulonephritis/sclerosis 4457 (31.2) 3168 (34.4) 1289 (25.5)
Pyelonephritis 1074 (7.5) 820 (8.9) 254 (5.0)
Polycystic kidneys adult type 2028 (14.2) 928 (10.1) 1100 (21.7)
Diabetes, type I 709 (5.0) 456 (5.0) 253 (5.0)
Diabetes, type II 370 (2.6) 138 (1.5) 232 (4.6)
Diabetes, type unknown 137 (1.0) 70 (0.8) 67 (1.3)
Hypertension 989 (6.9) 584 (6.3) 405 (8.0)
Renal vascular disease 135 (1.0) 71 (0.8) 64 (1.3)
Miscellaneous 2565 (18.0) 1784 (19.4) 781 (15.4)
Unknown/missing 1811 (12.7) 1193 (13.0) 618 (12.2)
Country (N, %) <0.001
Austria 845 (5.9) 464 (5.0) 381 (7.5)
Bosnia and Herzegovina 108 (0.8) 88 (1.0) 20 (0.4)
Belgium, Dutch-speaking 251 (1.8) 185 (2.0) 66 (1.3)
Belgium, French-speaking 237 (1.7) 147 (1.6) 90 (1.8)
Denmark 1112 (7.8) 711 (7.7) 401 (7.9)
Spain, Andalusia 432 (3.0) 251 (2.7) 181 (3.6)
Spain, Aragon 52 (0.4) 49 (0.5) 3 (0.1)
Spain, Asturias 39 (0.3) 36 (0.4) 3 (0.1)
Spain, Catalonia 1182 (8.3) 587 (6.4) 595 (11.8)
Spain, Cantabria 19 (0.1) 14 (0.2) 5 (0.1)
Spain, Extremadura 19 (0.1) 14 (0.2) 5 (0.1)
Spain, Galicia 228 (1.6) 118 (1.3) 110 (2.2)
Spain, Madrid 171 (1.2) 121 (1.3) 50 (1.0)
Spain, Murcia 27 (0.2) 11 (0.1) 16 (0.3)
Finland 119 (0.8) 102 (1.1) 17 (0.3)
France 3835 (26.9) 2423 (26.3) 1412 (27.9)
Greece 1267 (8.9) 1080 (11.7) 187 (3.7)
Iceland 99 (0.7) 71 (0.8) 28 (0.6)
Norway 1304 (9.1) 929 (10.1) 375 (7.4)
Sweden 2124 (14.9) 1215 (13.2) 909 (18.0)
United Kingdom, Scotland 805 (5.6) 596 (6.5) 209 (4.1)
KTx, kidney transplantation; KRT, kidney replacement therapy; SD, standard deviation; IQR, interquartile range; PRD, primary
renal disease; Tx, transplantation.
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recipients (median [IQR]: 38.6 [29.2–49.8] years versus
52.4 [44.5–60.0] years). The median (IQR) age at trans-
plantation was 39.7 (30.4–51.0) years in LRD transplant
recipients versus 53.5 (45.7–61.0) years among LUD
transplant recipients. More LUD transplant recipients
were males than LRD transplant recipients (68.7% vs.
63.8%).
The percentage of pre-emptive kidney transplants was
lower for LRD than for LUD transplant recipients,
29.4% (N = 2706) versus 37.5% (N = 1896), respec-
tively. Glomerulonephritis/sclerosis was the most com-
mon cause of ESKD in both groups (34.4% in LRD and
25.5% in LUD transplant recipients), followed by mis-
cellaneous causes (19.4% and 15.4%, respectively). Poly-
cystic kidney disease, adult type, was a more frequent
cause of ESKD in LUD (21.7%) than in LRD transplant
recipients (10.1%).
Trends over time in LRD and LUD kidney
transplantation
The 14 national and regional registries that had com-
plete data available over the total study period were
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Figure 1 Kidney transplants from living-related and living-unrelated donors in the period 1998–2017. Annual rates were standardized to the
mean age and sex distribution for the whole period. Abbreviations: LRD, living-related donor; LUD, living-unrelated donor; pmp, per million
population; APC, annual per cent change. Only those national and regional registries that had complete data available over the total study per-
iod from 1998 to 2017 were included: Austria, Dutch- and French-speaking Belgium, Denmark, Finland, Greece, Iceland, Norway, Sweden,
Scotland (UK) and the Spanish regions of Andalusia, Asturias, Catalonia and Cantabria.
Table 2. Risk of mortality and graft failure within 10 years after LRD (N = 9212) and LUD (N = 5063) kidney
transplantation.






Related donor 613 6.7 1 1
Unrelated donor 436 8.6 1.62 (1.43–1.83) 0.99 (0.87–1.13)
Graft failure
Related donor 1425 15.5 1 1
Unrelated donor 730 14.4 1.11 (1.02–1.22) 1.03 (0.94–1.14)
Death-censored graft failure
Related donor 956 10.4 1 1
Unrelated donor 402 7.9 0.90 (0.81–1.02) 1.19 (1.04–1.35)
HR, hazard ratio; 95% CI, 95% confidence interval.
*Multivariable model: recipient age at kidney transplantation, sex, primary renal disease, pre-transplant dialysis duration, era of
first kidney transplantation and country.
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time period on kidney transplantation (total N = 9835;
68.9%). From 1998 to 2017, there was an increase in
the rate of both LRD and LUD transplants (Fig. 1). The
LRD rate increased steadily with an average of 1.5% per
year (APC: 1.5 [0.8; 2.2]). LUD rates increased by
10.5% annually between 1998 and 2011 and seemed to
stabilize thereafter (APC: 2.4 [1.3; 6.2]).
Patient survival
The analysis of overall patient survival included patients
from all registries (N = 14 275). A total of 1049 patients
died within ten years after kidney transplantation, of
whom 613 (58.4%) were recipients of kidneys from
LRDs and 436 (41.6%) of kidneys from LUDs. In addi-
tion, 210 (1.5%) patients were lost to follow-up. The
median follow-up time was 6.5 (IQR: 3.1–11.0) years
for LRD transplants and 4.7 (IQR: 2.1–8.4) years for
LUD transplants.
The unadjusted five- and ten-year patient survival
probabilities were higher for LRD transplants (95.8%,
95% confidence interval [CI]: 95.4–96.3 and 88.7%,
95% CI: 87.8–89.6, respectively) than for LUD grafts
(93.5%, 95% CI: 92.6–94.3 and 82.0%, 95% CI: 80.1–
83.6, respectively). The results of Cox regression analysis
comparing the patient survival in the first ten years after
LRD and LUD kidney transplantation are presented in
Table 2. The unadjusted model showed a 62% higher
mortality among LUD transplant recipients when
compared with LRD transplant recipients (hazard ratio
[HR]: 1.62, 95% CI: 1.43–1.83). However, this associa-
tion disappeared after adjusting for potential con-
founders, including recipient age at kidney
transplantation, sex, PRD, duration of dialysis pre-
transplant, country and era of first kidney transplant
(HR: 0.99, 95% CI: 0.87–1.13). Additional analyses
showed that it was predominantly the adjustment for
age at transplantation that resulted in loss of the associ-
ation.
The distribution of the causes of death is depicted in
Fig. 2. This analysis included all countries and regions
except France. Among LRD transplant recipients, car-
diovascular disease was the most common cause of
death (24.6%), followed by malignancies (21.1%) and
infections (20.7%). In recipients of LUD grafts, cardio-
vascular disease was also the most common cause of
death (25.3%), followed by infections (24.3%) and
malignancies (21.8%) (absolute numbers are shown in
Table 3). The results of the unadjusted cause-specific
Cox regression analyses showed that when compared
with LRD, LUD transplant recipients had a higher risk
of death due to cardiovascular disease (HR: 1.70, 95%
CI: 1.30–2.22), infections (HR: 1.91, 95% CI: 1.45–2.53)
and malignancies (HR: 1.72, 95% CI: 1.29–2.29)
(Table 3); however, these associations disappeared after
adjustment for confounders.
Figure 3 presents the unadjusted survival of patients




















Cause of death distribuon
LRD
LUD
Percentage of paents 
Figure 2 Causes of death for kidney transplant recipients after living-related and living-unrelated kidney donor transplantation who died
within 10 years after transplantation (n = 892 recipients). Abbreviations: LRD, living-related donor; LUD, living-unrelated donor. Only those
national and regional registries with less than 25% missing or unknown causes of death were included: Austria, Bosnia and Herzegovina,
Dutch-speaking Belgium, French-speaking Belgium, Denmark, Finland, Greece, Iceland, Norway, Sweden, Scotland (UK) and the Spanish
regions of Andalusia, Aragon, Asturias, Catalonia, Cantabria, Extremadura, Galicia, Madrid and Murcia.
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in 1998–2007 and 2008–2017. Only the 14 registries with
data available over the entire study period were included
in this analysis (total N = 9835; 68.9%). Between 1998
and 2007, unadjusted patient survival was higher in the
LRD transplant recipients than in the LUD transplant
recipients, with 5-year survival probabilities of 95.3%
(95% CI: 94.5–96.1) and 90.4% (95% CI: 88.4–92.0),
respectively. Also in the period 2008–2017, the 5-year
patient survival probability was higher in the LRD trans-
plant recipients (95.9%, 95% CI: 95.1–96.6) than in the
LUD transplant recipients (93.7%, 95% CI: 92.4–94.8). In
both LRD and in LUD transplant recipients, the risk of
death was lower in the most recent time period. The results
of the adjusted Cox regression analyses by era showed no
difference in the risk of death between LUD and LRD
transplant recipients in 2008–2017 when compared to
1998–2007 (Table 4).
Graft survival
The analysis of graft survival included patients from all
registries (N = 14 275). Kidney graft failure (including
death as event) occurred in 2155 patients, of whom
1425 (66.1%) were LRD graft recipients and 730
(33.9%) LUD graft recipients. The unadjusted five- and
ten-year graft survival probabilities were higher after
LRD (89.2%, 95% CI: 88.5–89.9 and 75.0%, 95% CI:
73.7–76.2, respectively) than after LUD kidney trans-
plantation (87.8%, 95% CI: 86.7–88.8 and 72.6%, 95%
CI: 70.6–74.6, respectively), and the unadjusted Cox
regression model showed an 11% increase in graft fail-
ure among LUD graft recipients when compared to
LRD graft recipients (HR: 1.11, 95% CI: 1.02–1.22;
Table 2). Again, this association disappeared after
adjusting for the potential confounders, recipient age at
transplantation, sex, PRD, duration of dialysis pre-
transplant, country and era of first kidney transplant
(HR: 1.03, 95% CI: 0.94–1.14). Similar to the analyses
of patient survival, the adjustment for age was the prin-
cipal confounding factor that removed the effect of
donor source on graft survival.
There were 956 LRD and 402 LUD transplant recipi-
ents who remained alive after their graft failed. The
unadjusted analysis of death-censored graft failure
Table 3. Risk of mortality according to cause of death within 10 years after LRD (N = 6789) and LUD (N = 3651)
kidney transplantation.






Related donor 128 1.9 1.0 1.0
Unrelated donor 94 2.6 1.70 (1.30–2.22) 1.02 (0.77–1.36)
Cerebrovascular accident
Related donor 32 0.5 1 1
Unrelated donor 14 0.4 1.00 (0.53–1.88) 0.74 (0.38–1.46)
Infections
Related donor 108 1.6 1 1
Unrelated donor 90 2.5 1.91 (1.45–2.53) 1.19 (0.88–1.61)
Malignancies
Related donor 110 1.6 1 1
Unrelated donor 81 2.2 1.72 (1.29–2.29) 0.99 (0.73–1.35)
Miscellaneous
Related donor 97 1.4 1 1
Unrelated donor 58 1.6 1.38 (0.99–1.91) 0.90 (0.63–1.28)
Unknown/unavailable
Related donor 46 0.7 1 1
Unrelated donor 34 0.9 1.68 (1.08–2.62) 1.31 (0.79–2.17)
Only those national and regional registries with less than 25% missing or unknown causes of death were included: Austria,
Bosnia and Herzegovina, Dutch-speaking Belgium, French-speaking Belgium, Denmark, Finland, Greece, Iceland, Norway, Swe-
den, Scotland (UK) and the Spanish regions of Andalusia, Aragon, Asturias, Catalonia, Cantabria, Extremadura, Galicia, Madrid
and Murcia.
HR, hazard ratio; 95% CI, 95% confidence interval.
*Multivariable model: recipient age at kidney transplantation, sex, primary renal disease, pre-transplant dialysis duration, era of
first kidney transplantation and country.
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Number of paents at risk             Number of paents at risk             
LRD 2835       2774        2750       2720        2688        2656               LRD 3553       3170    2829       2457        2073        1685
LUD 1018     971          953          937          922          906            LUD 2429       2105      1830       1558        1245         977
Survival probabilies Survival probabilies
1 year                  2 year                   5 year                                  1 year                  2 year                  5 year
LRD 98.5                     97.8                       95.3                         LRD 99.1                     98.5                      95.9
(98.0-98.9)        (97.2-98.3)           (94.5-96.1)         (98.7-99.4)          (98.0-98.9)          (95.1-96.6)
LUD 96.2                     94.7                       90.4                     LUD 99.0                     98.2                      93.7 
(94.9-97.3)        (93.1-95.9)           (88.4-92.0)                   (98.5-99.3)          (97.5-98.7)          (92.4-94.8)
2008-20171998-2007
Logrank p<0.001 Logrank p = 0.003
Figure 3 Unadjusted 5-year patient survival probabilities for living-related donor (LRD) and living-unrelated donor (LUD) kidney transplants by
transplant era, in 1998–2007 and 2008–2017.
Table 4. Risk of mortality and of graft failure within 5 years after LRD and LUD kidney transplantation, by transplant



















Related donor 131 4.6% 1 1 106 3.0% 1 1
Unrelated donor 97 9.5% 2.13 (1.64–2.76) 1.32 (0.99–1.76) 102 4.2% 1.52 (1.15–1.99) 0.88 (0.66–1.18)
Graft failure
Related 348 12.3% 1 1 271 7.6% 1 1
Unrelated donor 153 15.0% 1.25 (1.03–1.51) 1.19 (0.96–1.46) 204 8.4% 1.17 (0.98–1.40) 1.03 (0.84–1.26)
Death-censored graft failure
Related 242 8.5% 1 1 180 6.8% 1 1
Unrelated donor 75 7.4% 0.88 (0.68–1.14) 1.16 (0.87–1.55) 123 5.1% 1.06 (0.84–1.33) 1.29 (1.00–1.68)
Only those national and regional registries that had complete data available over the total study period from 1998 to 2017
were included: Austria, Dutch- and French-speaking Belgium, Denmark, Finland, Greece, Iceland, Norway, Sweden, Scotland
(UK) and the Spanish regions of Andalusia, Asturias, Catalonia and Cantabria.
HR, hazard ratio; 95% CI, 95% confidence interval.
*Multivariable model: recipient age at kidney transplantation, sex, primary renal disease, pre-transplant dialysis duration and
country.
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showed no association between donor source and graft
failure (HR 0.90, 95% CI: 0.81–1.02), whereas the risk
of death-censored graft failure was higher in LUD than
in LRD transplant recipients (HR 1.19, 95% CI: 1.04–
1.35) after adjustment for confounders (Table 2).
When stratified by time period, the graft failure risk
was similar for LRD and LUD transplant recipients after
adjustment (Table 4). However, the increased risk of
death-censored graft failure for LUD transplant recipi-
ents was only statistically significant for the cohort in
2008–2017.
In the sensitivity analysis based on an age-matched
cohort (N = 8432), we found that both patient and
graft survival results were very similar to the findings of
the main analysis (Table S1).
Repeating the analyses only for those patients who
received a pre-emptive kidney transplant (N = 4602;
32.2%) resulted in similar adjusted HRs for patient,
graft and death-censored graft survival (0.94, 95% CI:
0.69–1.28; 1.15, 95% CI: 0.93–1.42; and 1.36, 95% CI:
1.04–1.79, respectively) compared with the analyses
using the entire dataset.
Discussion
This is the largest study on the effect of the living donor
source on the survival of patients undergoing kidney
transplantation reported to date. Using data from 21
European renal registries from 12 countries, we demon-
strate that kidney donation from both LRD and LUD
has increased over time. In addition, we found that
patient and graft survival (including death as event)
were similar among recipients of LRD and LUD kid-
neys, while death-censored graft survival was higher for
LRD transplants between 2008 and 2017. In both
groups, there was a trend towards improved patient and
graft survival over time.
Most previous studies that investigated the effect of
the living donor source on patient survival have demon-
strated a similar patient survival for recipients of LRD
versus LUD kidneys. Short-term (1–3 years) patient sur-
vival rates were comparable for LRD and LUDs grafts
in studies carried out in the United Kingdom, Italy,
Egypt and the United States [3,6,7,9]. An Iranian study
on long-term patient survival after LRD and LUD kid-
ney transplantation reported similar 10-year, 20-year
and 25-year survival probabilities [4,5]. By contrast, a
study in the United States showed that 10-year patient
survival among recipients of LUD transplants was worse
than that of LRD transplants (86% versus 63%, respec-
tively) [10]. This study was, however, carried out over
20 years ago and immunosuppressive therapies have
improved considerably since then.
In addition to patient survival, graft survival after
kidney transplantation is also of considerable interest to
potential donors, candidate recipients, health profes-
sionals and payers. Consistent with our findings, the
majority of previous studies found that graft survival
was similar for LRD and LUD graft recipients. Despite
the higher numbers of HLA mismatches among recipi-
ents of LUD kidneys, rejection rates were comparable in
both groups. This can likely be attributed to potent
immunosuppressive regimens [14].
Graft survival rates vary among kidney transplant
recipients due to several factors, including recipient and
donor characteristics, surgical techniques, delayed graft
function, presence of donor-specific HLA antibodies,
immunosuppressive regimens and acute rejection rates
[15,16]. The donor source plays a crucial role in graft
survival. Living donor kidneys are associated with better
graft survival when compared to deceased donor kid-
neys, mostly due to the better quality of the grafts (i.e.
less ischaemic injury), short ischaemia time, scheduled
surgery and higher probability of pre-emptive transplan-
tation [17–19].
While previous studies generally used overall graft
failure (including death as an event) as the primary out-
come, we also analysed whether the donor source was
associated with death-censored graft failure. Remark-
ably, we found that after adjustments, the risk of death-
censored graft failure was higher in LUD than in LRD
transplant recipients, whereas the overall risk of graft
failure was similar in both groups. We cannot explain
this discrepancy, but we speculate that it might be
explained by the fact that the higher risk of graft failure
without death (HR of 1.19) and the similar risk of
death for LUD transplant recipients (HR of 0.99) aver-
age out to the hazard ratio of 1.03 (95% CI: 0.94–1.14)
for overall graft failure (including death). We can also
speculate that our finding of a higher rate of graft fail-
ure among LUD transplants might be due to the older
age and the greater proportion of patients with diabetes
mellitus type II and hypertension (as the PRD) among
the LUD transplant recipients. Nevertheless, our study
showed high unadjusted ten-year graft survival rates for
both LRD and LUD transplant recipients (75% and
73%, respectively).
Our findings are important for healthcare profession-
als and policy makers when considering kidney trans-
plantation from living donors as a treatment modality
for KRT. This notion may lead to improvements in
health policies concerning kidney donations from non-
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relatives, making the procedure acceptable in countries
where it is considered illegal. In addition, awareness
about the possibility of altruistic donation could be
increased in the general population. Our results are also
important for patients, so that they can discuss poten-
tial donation with genetically non-related acquaintances
leading to more people coming forward as potential liv-
ing donors.
Because both short-term and long-term patient and
graft survival rates were found to be similar for LRD
and LUD transplants, health policies should be advo-
cated for promoting living donation and recruiting
more unrelated organ donors.
In our study, we found that 32.2% of living donor kid-
ney transplants were pre-emptive transplants. Interest-
ingly, the percentage of pre-emptive transplants was lower
for LRD than for LUD graft recipients. Efforts to promote
living kidney donation should also aim at increasing the
number of pre-emptive transplants to further improve
recipient and graft survival.
The most important strength of our study lies in the
very large sample size and relatively long follow-up time.
Data from 21 national and regional renal registries in 12
European countries are included, covering a total popula-
tion of 176 million individuals over a 20-year time period
[20], with no missing data except from the cause of death
(34%). Our study is, however, limited by the lack of
important information on the recipients, such as comor-
bid conditions and transplant-related factors, including
HLA matching, immunosuppressive regimens and acute
rejection episodes, all of which influence kidney transplant
outcomes. Moreover, information on the donors, includ-
ing their age, was unavailable, which made it impossible to
adjust for these factors. We believe that most donor and
transplant recipient factors are not very different for LUD
versus LRD transplants. However, there may be a differ-
ence in donor age since younger patients not infrequently
receive a donor kidney from an older LRD, while this
occurs less often with LUD transplants. It is conceivable
that higher donor age could have a negative impact on
patient and graft survival among LRD kidney recipients
when compared with recipients of LUD grafts [21,22]. In
addition, these findings may not be generalizable to other
countries where transplant practice may vary.
In conclusion, the frequency of kidney transplanta-
tion from living donors increased over the past
20 years. We showed a comparable patient and graft
survival for both LRD and LUD kidney transplants,
with improvements of both occurring over time, partic-
ularly in the most recent years. Only the risk of death-
censored graft loss was higher for LUD transplant
recipients than LRD transplant recipients. Our findings
highlight the importance of increasing awareness of liv-
ing kidney donation, especially from unrelated donors.
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